KIR2DS2high NK cells from CLL patients showed significantly enhanced activation in the absence of anti-CD20 mAb compared to KIR2DL3/L2/S2- (p<0.05) but not KIR2DL3/L2high NK cells (Figures 2F, G). Here, KIR2DL3 is linked to B-cell chronic lymphocytic leukemia.